Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer

Table 2

Toxicities.

	Gr 2	Gr 3	Gr 4
GU bleeding	1 (6.6%)
Thromboembolism			1 (6.6%)
Proteinuria	2 (13.3%)	1 (6.6%)
HTN	7 (46.6%)	2 (13.3%)
Diarrhea	1 (6.6%)
Nausea/vomiting	1 (6.6%)
Anemia	1 (6.6%)